Cosmos Health Inc. Expands Share Repurchase Program While Reporting Strong Revenue Growth

Cosmos Health Inc. (NASDAQ: COSM), a diversified global healthcare group that develops and markets generic pharmaceuticals, nutraceuticals, over‑the‑counter medications, and medical devices, announced a significant expansion of its share repurchase program and reported robust revenue performance for the second quarter and first half of 2026.

Share Repurchase Activity

  • Total Shares Repurchased
  • As of July 6 2026, the company had repurchased 3,640,000 shares for approximately $700,000 under a $5 million program.
  • On July 7 2026, an additional 230,000 shares were purchased at an average price of $0.2539 per share, bringing the cumulative repurchases to 3,870,000 shares and an estimated total outlay of $758,000.
  • Program Structure
  • The buyback may be executed in the open market, through privately negotiated transactions, or other permissible means in accordance with SEC Rules 10b‑5‑1 and 10b‑18.
  • The company indicated that it will continue making open‑market repurchases subject to market conditions.

Revenue Performance

  • Second‑Quarter 2026
  • Preliminary revenue for Q2 2026 was $19.4 million, a year‑over‑year increase of 31.5 % relative to $14.75 million in Q2 2025.
  • First Half 2026
  • Consolidated revenue for the first six months of 2026 reached $37.3 million, up 31 % from $28.46 million in H1 2025.
  • Implications
  • The revenue growth reflects the company’s continued expansion of its product portfolio and market reach within the health‑care services sector.

Market Context

  • Share Price and Market Capitalization
  • The stock closed at $0.2567 on July 6 2026, with a 52‑week high of $1.32 (October 9 2025) and a 52‑week low of $0.162 (June 29 2026).
  • Market capitalization stands at approximately $14.67 million.
  • Valuation
  • The price‑earnings ratio is ‑0.42, indicating that the company is not yet generating earnings sufficient for a positive P/E.

Summary

Cosmos Health Inc. has intensified its share repurchase program, buying back nearly 4 million shares at an average price below its 52‑week low, while simultaneously reporting a substantial rise in revenue for both the second quarter and the first half of 2026. These developments suggest that the company is leveraging its capital to return value to shareholders while maintaining growth momentum in its product lines.